Athira Pharma completes patient dosing in Phase 2/3 trial of fosgonimeton in AD
Athira Pharma, Inc. (NASDAQ: ATHA), a prominent biopharmaceutical company specializing in neurodegenerative diseases, has announced the completion of patient dosing in the Phase 2/3 LIFT-AD ... Read More
FDA approves Eli Lilly’s Kisunla for Alzheimer’s treatment
The U.S. Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt), an Alzheimer's treatment developed by Eli Lilly and Company (NYSE: LLY). This treatment, specifically ... Read More
Eisai initiates rolling submission for Leqembi autoinjector BLA to FDA
BioArctic AB's partner Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb ... Read More
BioArctic and Eisai team up on Alzheimer’s disease candidate BAN2802
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has entered into a new research evaluation agreement with Eisai Co., Ltd. The collaboration focuses on BAN2802, a ... Read More
Breakthrough Alzheimer’s treatments on the horizon: New drugs and potential vaccine
Global Health Update — Promising developments in the fight against Alzheimer's disease could significantly alter the landscape of treatment and prevention within the next decade. ... Read More